February 2019 Briefing – Hematology & Oncology

Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for February 2019. This roundup includes the latest research news from journal […]

Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for February 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Mental Health Disorders Up After Head & Neck Cancer Diagnosis

THURSDAY, Feb. 28, 2019 (HealthDay News) — In patients with head and neck cancer (HNC), the prevalence of mental health disorders (MHDs) is significantly higher after cancer diagnosis, according to a study published online Feb. 28 in JAMA Otolaryngology-Head & Neck Surgery.

Abstract/Full Text (subscription or payment may be required)

Robotically Assisted Devices Not Approved for Cancer Surgery

THURSDAY, Feb. 28, 2019 (HealthDay News) — The use of robotically assisted surgical devices for breast removal and other cancer-related surgeries is not approved by the U.S. Food and Drug Administration because there is no proof of its safety or effectiveness in such cases, the agency says in a warning to doctors and patients.

More Information

Performance Improvement Sustained After DBT Adoption

THURSDAY, Feb. 28, 2019 (HealthDay News) — Performance improvements after adoption of digital breast tomosynthesis (DBT) relative to digital mammography (DM) performance have been sustained, regardless of DBT volume, according to a study published online Feb. 26 in Radiology.

Abstract/Full Text (subscription or payment may be required)

Intervention Can Reduce Racial Differences in Lung Cancer Care

THURSDAY, Feb. 28, 2019 (HealthDay News) — An intervention that includes race-specific feedback and real-time electronic warnings can reduce racial differences in care for early-stage lung cancer, according to a study published online Feb. 4 in Cancer Medicine.

Abstract/Full Text

Lymphadenectomy Does Not Up Survival in Advanced Ovarian Cancer

WEDNESDAY, Feb. 27, 2019 (HealthDay News) — For patients with advanced ovarian cancer who have undergone intra-abdominal macroscopically complete resection and have clinically negative lymph nodes, lymphadenectomy is not associated with longer overall or progression-free survival, according to a study published in the Feb. 28 issue of the New England Journal of Medicine.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Adjuvant Tx for Early Testicular Cancer Does Not Harm Sperm

WEDNESDAY, Feb. 27, 2019 (HealthDay News) — For clinical stage I testicular cancer (TC) patients, adjuvant treatment after orchiectomy has no long-term significant effect on sperm production, according to a study published online Feb. 25 in the Annals of Oncology.

Abstract/Full Text

Decline Observed in HPV Type 16/18 Cervical Precancers in U.S.

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
Page 1 of 10
Next »